Advertisement

Topics

SU2C/Amgen Company Profile

14:32 EST 17th November 2017 | BioPortfolio


News Articles [540 Associated News Articles listed on BioPortfolio]

10 SU2C Catalyst® collaborative clinical trial projects combine treatments from 9 pharma

(Entertainment Industry Foundation) 10 SU2C Catalyst® clinical trial projects awarded, collaborating across academic /industry borders, and correlated translational research will deepen understanding...

Amgen Spain: Success in Europe

In this episode of PharmaTelevision News Review, Fintan Walton talks with Jordi Marti, CEO at Amgen Spain. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss: • Why Amgen decided to...

TGen receives $2.5 million SU2C grant for new pancreatic cancer clinical trial

(The Translational Genomics Research Institute) Stand Up To Cancer (SU2C) has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute (TGen) to investigate a revol...

Kirin-Amgen JV To Become Wholly-owned Subsidiary Of Amgen

THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) said that the company and Kirin Holdings (KNBWF.PK, KNBWY.PK) have agreed that Kirin-Amgen, a joint venture between the two companies, will redeem Kirin...

Kirin-Amgen Joint Venture To Become Wholly-Owned Subsidiary Of Amgen

$780 Million Payment to be Funded From Joint Venture's Existing Cash Holdings Kyowa Hakko Kirin to Continue as Licensee in Asia THOUSAND OAKS, Calif., Oct. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AM...

TGen awarded $2.5 million SU2C grant to test new method of treating pancreatic cancer

Stand Up To Cancer has awarded a $2.5 million SU2C CatalystR grant to the Translational Genomics Research Institute to investigate a revolutionary new method of treating pancreatic cancer, one of the ...

New SU2C-Lustgarten Foundation team aims to apply CAR T-cell therapy to pancreatic cancer

(American Association for Cancer Research) Stand Up To Cancer is supporting a new translational research team to explore how a type of immunotherapy that has been very successful in blood cancers can ...

Mirati Therapeutics ' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients

SAN DIEGO, Oct. 12, 2017 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage oncology biotechnology company, announced today that the Company has been included in the SU2C Cataly...

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Nplate [Amgen Inc]

These highlights do not include all the information needed to use Nplate safely and effectively. See full prescribing information for Nplate. Nplate (romiplostim)For subcutaneous injection Initial U.S...

Neulasta [AMGEN INC]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta. Neulasta (pegfilgrastim) injection, for subcutaneous u...

Neulasta [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use Neulasta safely and effectively. See full prescribing information for Neulasta.Neulasta (pegfilgrastim) injection, for subcutaneous us...

Sensipar [Amgen, Inc]

These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar. Sensipar (cinacalcet) TabletsInitial U.S. Approval: 20...

Xgeva [AMGEN]

These highlights do not include all the information needed to use XGEVA™ safely and effectively. See full prescribing information for XGEVA. Xgeva (denosumab)injection, for subcutaneous useInitial U...

PubMed Articles [6 Associated PubMed Articles listed on BioPortfolio]

Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS.

The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics.

Letter--The Authors Respond.

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or int...

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...

Accelerating Patient Access to Novel Biologics using Stable Pool-derived Product for Non-clinical Studies and Single Clone-derived Product for Clinical Studies.

Cell cloning and subsequent process development activities are on the critical path directly impacting the timeline for advancement of next generation therapies to patients with unmet medical needs. T...

Clinical Trials [18 Associated Clinical Trials listed on BioPortfolio]

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen,) based on maintenance of hemoglobin (Hb) levels and s...

An Open Label Treatment Extension Study of AMG 706

This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate A...

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Chemotherapy regimens for pancreatic cancer can now stabilize a patient's cancer and/or place some patients in remission or partial remission. The challenge now is to find options for main...

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit dosing (µg) in thrombocytopenic subjects with ITP.

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at ...

Companies [46 Associated Companies listed on BioPortfolio]

SU2C/Amgen

Amgen, Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen

The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live...

Amgen AB

Amgen är ett världsledande bioteknologiskt läkemedelsföretag. Genom vetenskapliga upptäckter och innovationer har företaget under 25 års tid bidragit till att radikalt förbättra människors l...

More Information about "SU2C/Amgen" on BioPortfolio

We have published hundreds of SU2C/Amgen news stories on BioPortfolio along with dozens of SU2C/Amgen Clinical Trials and PubMed Articles about SU2C/Amgen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SU2C/Amgen Companies in our database. You can also find out about relevant SU2C/Amgen Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record